Patents by Inventor Xiangbin Xu

Xiangbin Xu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240000838
    Abstract: Compositions and methods for treating diseases associated with expression of cluster differentiation 33 (CD33) and/or cluster differentiation 5 (CD5) involve two chimeric antigen receptors (CARs) specific to CD33 and CD5 and T cells with CD33 and CD5 dual-CAR. Methods of administering a genetically modified T cell expressing the dual-CAR can be used for autologous and allogeneic treatment of T cell malignancies.
    Type: Application
    Filed: November 24, 2021
    Publication date: January 4, 2024
    Inventors: Daofeng LIU, Pei-Yun TSAI, Zhongdong SHI, Xiangbin XU
  • Patent number: 9682070
    Abstract: Pharmaceutical compositions and methods for treating or preventing an inflammatory condition in a patient are disclosed. The pharmaceutical compositions and methods include the use of vincamine or a vincamine derivative, either alone or in combination with one or more additional therapeutic agents, including a steroid (preferably a corticosteroid), an angiotensin II receptor (type 1) antagonist, an angiotensin-converting enzyme (ACE) inhibitor, and a non-steroidal anti-inflammatory drug.
    Type: Grant
    Filed: December 15, 2015
    Date of Patent: June 20, 2017
    Assignee: University of Rochester
    Inventors: Chen Yan, Jian-Dong Li, Bradford Berk, Kye-Im Jeon, Xiangbin Xu
  • Publication number: 20160256444
    Abstract: Pharmaceutical compositions and methods for treating or preventing an inflammatory condition in a patient are disclosed. The pharmaceutical compositions and methods include the use of vincamine or a vincamine derivative, either alone or in combination with one or more additional therapeutic agents, including a steroid (preferably a corticosteroid), an angiotensin II receptor (type 1) antagonist, an angiotensin-converting enzyme (ACE) inhibitor, and a non-steroidal anti-inflammatory drug.
    Type: Application
    Filed: December 15, 2015
    Publication date: September 8, 2016
    Inventors: Chen Yan, Jian-Dong Li, Bradford Berk, Kye-Im Jeon, Xiangbin Xu
  • Patent number: 9241932
    Abstract: Pharmaceutical compositions and methods for treating or preventing an inflammatory condition in a patient are disclosed. The pharmaceutical compositions and methods include the use of vincamine or a vincamine derivative, either alone or in combination with one or more additional therapeutic agents, including a steroid (preferably a corticosteroid), an angiotensin II receptor (type 1) antagonist, an angiotensin-converting enzyme (ACE) inhibitor, and a non-steroidal anti-inflammatory drug.
    Type: Grant
    Filed: February 26, 2014
    Date of Patent: January 26, 2016
    Assignee: UNIVERSITY OF ROCHESTER
    Inventors: Chen Yan, Jian-Dong Li, Bradford Berk, Kye-Im Jeon, Xiangbin Xu
  • Publication number: 20140296273
    Abstract: Pharmaceutical compositions and methods for treating or preventing an inflammatory condition in a patient are disclosed. The pharmaceutical compositions and methods include the use of vincamine or a vincamine derivative, either alone or in combination with one or more additional therapeutic agents, including a steroid (preferably a corticosteroid), an angiotensin II receptor (type 1) antagonist, an angiotensin-converting enzyme (ACE) inhibitor, and a non-steroidal anti-inflammatory drug.
    Type: Application
    Filed: February 26, 2014
    Publication date: October 2, 2014
    Inventors: Chen Yan, Jian-Dong Li, Bradford Berk, Kye-Im Jeon, Xiangbin Xu
  • Publication number: 20100221340
    Abstract: Pharmaceutical compositions and methods for treating or preventing an inflammatory condition in a patient are disclosed. The pharmaceutical compositions and methods include the use of vincamine or a vincamine derivative, either alone or in combination with one or more additional therapeutic agents, including a steroid (preferably a corticosteroid), an angiotensin II receptor (type 1) antagonist, an angiotensin-converting enzyme (ACE) inhibitor, and a non-steroidal anti-inflammatory drug.
    Type: Application
    Filed: September 16, 2008
    Publication date: September 2, 2010
    Applicant: UNIVERSITY OF ROCHESTER
    Inventors: Chen Yan, Jian-Dong Li, Bradford Berk, Kye-im Jeon, Xiangbin Xu